Remove tag negotiations
article thumbnail

STAT+: Medicare will take R&D costs, effectiveness into account when it negotiates drug prices. But studies show that doesn’t affect prices

STAT News

By law, Medicare will have to take a medication’s efficacy and its research and development costs into account when it starts to negotiate drug prices — but recent research shows pharma companies ignore those factors when they pick prices for their products. But neither factor has much effect, the studies concluded.

Drugs 98
article thumbnail

Medicare savings won’t make a dent in healthcare costs

World of DTC Marketing

SUMMARY: Allowing Medicare to negotiate drug prices is popular with voters because the media has been focused on the high price of some drugs, but this measure won’t lead to lower healthcare costs. The drug industry is trying to convince voters that government negotiations with drug companies will lead to less innovation.

Drugs 222
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Risk-sharing agreements are growing at a rate of 24%

Pharmaceutical Technology

This is not the first treatment to come with a high price tag. Most finance-based agreements are discount schemes, including simple discounts, compulsory discounts on ex-factory prices, or other types of discount price negotiations.

article thumbnail

STAT+: Pharmalittle: New York officials press pharmacy chains over abortion pill; Sanders pushes bill for $20 insulin cap

STAT News

Enjoy, and see you soon … By law, Medicare will have to take a medication’s efficacy and its research and development costs into account when it starts to negotiate drug prices — but recent research shows pharma companies ignore those factors when they pick prices for their products , STAT explains. Two But be safe.

Insulin 96
article thumbnail

Cartherics grants licence for CTH-004 to Shunxi

Pharmaceutical Technology

Shunxi will also hold an option to negotiate rights to other CAR-T products, which include the licenced IP. CTH-004 is developed by genetically altering patient T cells for inserting a chimeric antigen receptor (CAR) to target a marker (TAG-72) on ovarian cancer cells and delete genes which are involved in T cell function suppression.

article thumbnail

Grand Rounds February 16, 2024: Clinical Implications of the MINT Trial: p=0.07 (Jeffrey Carson, MD, MACP)

Rethinking Clinical Trials

There was some negotiation about how we would describe some of our conclusions, but overall, it was a good experience. Tags #pctGR, @Collaboratory1 The post Grand Rounds February 16, 2024: Clinical Implications of the MINT Trial: p=0.07 (Jeffrey Carson, MD, MACP) appeared first on Rethinking Clinical Trials.

Trials 130
article thumbnail

NICE reaches a deal with Roche on access to oral SMA drug Evrysdi

pharmaphorum

The cost-effectiveness agency had turned down Evrysdi (risdiplam) in draft guidance published in June, saying it was too expensive, but after negotiations with Roche has reached a deal that will make the drug available to around 1,500 people in England. million price tag make it is the most expensive treatment ever approved for NHS funding.

Drugs 91